Compare ACADIA Pharmaceuticals Inc. (ACAD) vs AGNC Investment Corp (AGNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs AGNC Investment Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.43 (market cap $5.07B), while AGNC Investment Corp trades at $10.97 (market cap $12.89B). The key difference: AGNC Investment Corp is far larger — about 2.5× ACADIA Pharmaceuticals Inc.'s market cap, and AGNC Investment Corp pays a 13.24% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AGNC | |
|---|---|---|
Market Cap | $5.07B | $12.89B |
Sector | Health | Financials |
52-Week High | $29.45 | $12.17 |
52-Week Low | $20.06 | $9.58 |
Enterprise Value | $4.19B | — |
Dividend Yield | — | 13.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.38, down 3.5% over the past day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.18 EPS versus $0.07 expected, and raised its 2026 revenue outlook. Revenue growth has accelerated from $517M in 2022 to $1.07B in 2025, with net income turning positive in 2024 and reaching $391M in 2025.
The outlook remains positive with 70% analyst buy ratings and a $33.89 consensus price target, though risks include high RSI levels suggesting overbought conditions and dependence on key drug trials. Near-term catalysts include Phase 2 data for remlifanserin in Alzheimer's psychosis, expected by October 2026.
AGNC Investment Corp. trades at $10.96, up 0.64% with a bullish technical signal. The mortgage REIT shows strong profitability with 94.38% net income margin and 21.67% ROE, though Q4 2025 EPS missed expectations. Recent dividend declarations of $0.12 per share maintain the 13.5% yield that attracts income investors. Cash flow trends show operational improvement with $886M operating cash flow projected for 2026.
The stock presents income opportunity with high dividend yield but faces interest rate sensitivity risks. Analyst consensus leans neutral with $11.30 price target, suggesting limited upside from current levels. Mortgage market volatility and leverage exposure remain key considerations for investors seeking yield in the mREIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →
